INO
Price
$0.84
Change
+$0.04 (+5.00%)
Updated
Oct 22 closing price
Capitalization
86.74M
18 days until earnings call
Intraday BUY SELL Signals
ORMP
Price
$4.12
Change
-$0.02 (-0.48%)
Updated
Oct 22 closing price
Capitalization
171.38M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INO vs ORMP

INO vs ORMP Comparison Chart in %
View a ticker or compare two or three
VS
INO vs. ORMP commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a StrongBuy and ORMP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for INO with price predictions
Oct 21, 2026

INO in upward trend: price may jump up because it broke its lower Bollinger Band on October 21, 2026

INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 44 cases where INO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for INO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 59 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

INO moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INO crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for INO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.844) is normal, around the industry mean (2.988). P/E Ratio (-0.814) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ORMP with price predictions
Oct 21, 2026

ORMP's Indicator enters downward trend

The Aroon Indicator for ORMP entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 156 of the 186 cases the stock moved lower. This puts the odds of a downward move at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 65 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.540) is normal, around the industry mean (2.988). P/E Ratio (0.972) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.243) settles around the average of (123.903) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
INO vs ORMP: Fundamental Ratings
INO
ORMP
OUTLOOK RATING
1..100
5661
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10015
PRICE GROWTH RATING
1..100
7743
P/E GROWTH RATING
1..100
1792
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (66) in the Pharmaceuticals Other industry is in the same range as INO (89) in the Medical Specialties industry. This means that ORMP’s stock grew similarly to INO’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that ORMP’s stock grew similarly to INO’s over the last 12 months.

ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for INO (100) in the Medical Specialties industry. This means that ORMP’s stock grew significantly faster than INO’s over the last 12 months.

ORMP's Price Growth Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for INO (77) in the Medical Specialties industry. This means that ORMP’s stock grew somewhat faster than INO’s over the last 12 months.

INO's P/E Growth Rating (17) in the Medical Specialties industry is significantly better than the same rating for ORMP (92) in the Pharmaceuticals Other industry. This means that INO’s stock grew significantly faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
72%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (INO: $0.80 vs. ORMP: $4.14)
Brand notoriety: INO: Notable vs. ORMP: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 320% vs. ORMP: 49%
Market capitalization -- INO: $86.74M vs. ORMP: $171.38M
INO [@Biotechnology] is valued at $86.74M. ORMP’s [@Biotechnology] market capitalization is $171.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 1 FA rating(s) are green while ORMP’s FA Score has 1 green FA rating(s).

  • INO’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 1 green, 4 red.
According to our system of comparison, ORMP is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • INO’s TA Score: 4 bullish, 5 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both INO and ORMP are a bad buy in the short-term.

Price Growth

INO (@Biotechnology) experienced а -19.34% price change this week, while ORMP (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

INO is expected to report earnings on Nov 09, 2026.

ORMP is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
INO
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KIQQ24.620.25
+1.02%
KraneShares InspereX Nasdaq Dynamic Buffered High Income Index ETF (KIQQ)
XV24.080.12
+0.50%
Simplify Target 15 Distribution ETF
EFR10.120.04
+0.40%
Eaton Vance Senior Floating-Rate Fund
XNAV87.44N/A
N/A
FundX Aggressive ETF (XNAV)
RAVI75.10-0.05
-0.07%
Northern Trust Ultra-Short Income ETF (RAVI)